Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Lucid Cap Mkts

Key Points

• Lucid Capital Markets upgraded Turn Therapeutics to “strong buy,” joining LADENBURG THALM/SH/SH, while other analysts remain mixed. MarketBeat reports an overall “Moderate Buy” consensus and an average price target of $9.00.
• Turn Therapeutics shares opened at $13.26, down 1.9%, with a market capitalization of approximately $395 million. The stock has traded between $2.57 and $26.50 over the past year.
• The company reported a quarterly loss of $0.20 per share, and analysts expect a full-year loss of $0.40 per share. Several institutional investors, including BlackRock and Bank of America, recently initiated positions.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was upgraded by Lucid Cap Mkts to a "strong-buy" rating in a note issued to investors on Thursday, Zacks reports.

Several other brokerages have also recently weighed in on TTRX. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Weiss Ratings downgraded shares of Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 18th. WBB Securities reissued a "sell" rating and set a $10.00 price target on shares of Turn Therapeutics in a research report on Monday, September 14th. Zacks Research upgraded shares of Turn Therapeutics to a "hold" rating in a report on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Turn Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $9.00.

Turn Therapeutics Stock Down 1.9%

Shares of Turn Therapeutics stock opened at $13.26 on Thursday. The stock's 50-day moving average is $10.60 and its 200 day moving average is $6.95. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The firm has a market cap of $394.99 million and a price-to-earnings ratio of -45.72. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current year.

Institutional Trading of Turn Therapeutics

Several hedge funds have recently added to or reduced their stakes in TTRX. Bank of America Corp DE bought a new stake in shares of Turn Therapeutics in the 2nd quarter worth approximately $103,000. Tamar Securities LLC purchased a new stake in Turn Therapeutics in the fourth quarter worth $59,000. Jefferies Financial Group Inc. purchased a new stake in Turn Therapeutics in the second quarter worth $119,000. Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics in the second quarter valued at $242,000. Finally, BlackRock Inc. bought a new stake in shares of Turn Therapeutics in the second quarter valued at $282,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.